Abstract
Ovarian cancer (OC) is one of the gynecological cancers with the worst prognosis, causing 185,000 deaths and 300,000 women diagnosed worldwide annually. A major challenge to improve treatment outcomes in ovarian cancer is the lack of effective screening methods for early detection. microRNAs modulate gene expression in various cancer types and are recognized as promising biomarkers that could lead to clinical applications, since their profiles differ in healthy and cancer groups of people. Identification of tumor-specific microRNAs presents a powerful opportunity to potentially reduce cancer mortality through early detection.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
